Cellular factors may enable squamous carcinoma cells to overcome TGFβ- mediated repression of CDK2 activity

Oral Oncology

Volumn 34, Issue 1, 1998, Pages 52-57

  Lesaca, E E ^a   Ensley, J F ^b   Yeudall, W A ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Cell cycle; Cip1; Cyclin dependent kinase; Oral cancer; p21; Squamous cell carcinoma; Transforming growth factor; WAF1

Indexed keywords

CYCLIN DEPENDENT KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CANCER IMMUNOLOGY; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; DNA SYNTHESIS; IMMUNOLOGICAL TOLERANCE; MOUSE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

EID: 0031944138     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(97)00023-7     Document Type: Article

References (49)

1. [1] Levine AJ. Tumor suppressor genes. Annual Review of Biochemistry 1993;62:623-651.
2. [2] Akhurst RJ. The transforming growth factor β family in vertebrate embryogenesis. In Nilsen-Hamilton M, editor. Growth factors in signal transduction and development. New York: Wiley-Liss, 1994: pp. 97-122.
3. [3] Wrana JL, Attisano L, Weiser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature 1994;370:341-347.
4. [4] Kawabata M, Imamura T, Miyazono K, Engel ME, Moses HL. Interaction of the transforming growth factor β type 1 receptor with farnesyl-protein transferase-alpha. Journal of Biological Chemistry 1995;270:29628-29631.
5. [5] Wang T, Danielson PD, Li BY, Shah PC, Kim SD, Donahoe PK. The p21 (RAS) farnesyltransferase alpha subunit in TGF-β and activin signaling. Science 1996;271:1120-1122.
6. ras by transforming growth factor β in epithelial cells. Journal of Biological Chemistry 1992;267:5029-5031.
7. [7] Shibuya H, Yamaguchi K, Shirakabe K, et al., TAB1: an activator of the TAK1 MAPKKK in TGF-β signal transduction. Science 1996;272:1179-1182.
8. [8] Yamaguchi K, Shirakabe K, Shibuya H, et al., Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 1995;270:2008-2011.
9. mapk in proliferating cultures of epithelial cells. Journal of Biological Chemistry 1995;270:7117-7124.
10. [10] Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massague J. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 1990;62:175-185.
11. 1/S-phase growth arrest. Molecular and Cellular Biology 1991;11:1185-1194.
12. [12] Ewen ME, Sluss HK, Whitehouse LL, Livingston DM. TGFβ inhibition of cdk4 synthesis is linked to cell cycle arrest. Cell 1993;74:1009-1020.
13. 1 cyclins and cyclin-dependent protein kinases. Proceedings of the National Academy of Sciences of the USA 1993;90:10315-10319.
14. [14] Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science 1993;260:536-539.
15. 1 cell-cycle arrest. Genes and Development 1995;9:204-217.
16. [16] Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes and Development 1995;9:1149-1163.
17. [17] Yeudall WA, Jakus J. Cyclin kinase inhibitors add a new dimension to cell cycle control. Oral Oncology, European Journal of Cancer 1995;31B:291-298.
18. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994;371:257-260.
19. [19] Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang X-F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proceedings of the National Academy of Sciences of the USA 1995;92:5545-5549.
20. [20] Haddow S, Fowlis DJ, Parkinson K, Akhurst RJ, Balmain A. Loss of growth control by TGFβ occurs at a late stage of mouse skin carcinogenesis and is independent of ras gene inactivation. Oncogene 1988;6:1465-1470.
21. [21] Missero C, Cajal SRY, Dotto GP. Escape from transforming growth factor β control and oncogene cooperation in skin tumor development. Proceedings of the National Academy of Sciences of the USA 1991;88:9613-9617.
22. [22] Manning AM, Williams AC, Game SM, Paraskeva C. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor β (TGF-β): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-β. Oncogene 1991;6:1471-1476.
23. [23] Game SM, Huelsen A, Patel, V, et al. Progressive abrogation of TGF-β1 and EGF growth control is associated with tumour progression in ras-transfected human keratinocytes. International Journal of Cancer 1992;52:461-470.
24. [24] Prime SS, Matthews JB, Patel V, et al. TGF-β receptor regulation mediates the response to exogenous ligand but is independent of the degree of cellular differentiation. International Journal of Cancer, 1994;56:406-412.
25. [25] Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gesmonde J, Vellucci VF, Reiss M. Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells. Cancer Research 1995;55:3982-3987.
26. [26] Taipale J, Keski-Oja J. Hepatocyte growth factor releases epithelial and endothelial cells from growth arrest induced by transforming growth factor β1. Journal of Biological Chemistry 1996;271:4342-4348.
27. [27] Yeudall WA, Crawford RY, Ensley JF, Robbins K. C. MTS1/ CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 1994;15:2683-2686.
28. [28] Boukamp P, Petrusevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. Journal of Cell Biology 1988;106:761-771.
29. [29] Parkinson EK, Yeudall, WA, Epidermis. In: Freshney, RI, editor. Culture of Epithelial Cells. New York, Wiley-Liss, 1992: 59-80.
30. [30] Jakus J, Yeudall WA. Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells. Oncogene 1996;12:2369-2376.
31. [31] Harlow E, Lane DP. Antibodies: A laboratory manual. New York, Cold Spring Harbor Laboratory Press, 1988.
32. [32] Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Molecular and Cellular Biology 1994;14:2077-2086.
33. [33] Akhurst RJ, Fee F, Balmain A. Localized production of TGFβ mRNA in tumour promoter-stimulated mouse epidermis. Nature 1988;331:363-365.
34. [34] El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
35. [35] El-Deiry WS, Harper JW, O'Connor PM, et al., WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Research 1994;54:1169-1174.
36. [36] Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Research 1994;54:3391-3395.
37. [37] Decker SJ. Nerve growth factor-induced growth arrest and induction of p21Cip1/WAF1 in NIH-3T3 cells expressing TrkA. Journal of Biological Chemistry 1995;270:30841-30844.
38. [38] Qin X.-Q, Livingston DM, Ewen ME, Sellers WR, Arany Z, Kaelin WG., Jr. The transcription factor E2F-1 is a downstream target of RB action. Molecular and Cellular Biology 1995;15:742-755.
39. [39] Schwarz JK, Bassing CH, Kovesdi I, et al. Expression of the E2F1 transcription factor overcomes type β transforming growth factor-mediated growth suppression. Proceedings of the National Academy of Sciences of the USA 1995;92:483-487.
40. [40] Lin D, Fiscella M, O'Connor PM, et al. Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest. Proceedings of the National Academy of Sciences of the USA 1994;91:10079-10083.
41. [41] Mizuguchi G, Nakagoshi H, Nagase T, et al. DNA binding activity and transcriptional activator function of the human B-myb protein compared with c-MYB. Journal of Biological Chemistry 1990;265:9280-9284.
42. [42] Nakagoshi H, Kanei-Ishii C, Sawazaki T, Mizuguchi G, Ishii S. Transcriptional activation of the c-myc gene by the c-myb and B-myb gene products. Oncogene 1992;7:1233-1240.
43. [43] Arsura M, Introna M, Passerini F, Mantovani A, Golay J. B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines. Blood 1992;79:2708-2716.
44. [44] Travali S, Reiss K, Ferber A, et al. Constitutively activated c-myb abrogates the requirement for insulin-like growth factor 1 in 3T3 fibroblasts. Molecular and Cellular Biology 1991;11:731-736.
45. [45] Sala A, Calabretta B. Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression. Proceedings of the National Academy of Sciences of the USA 1992;89:10415-10419.
46. [46] Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes and Development 1995;9:1831-1845.
47. [47] Olopade OI, Bohlander SK, Pomykala H, et al. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics 1992;14:437-443.
48. [48] Loughran O, Edington KG, Berry IJ, Clark LJ, Parkinson EK. Loss of heterozygosity of chromosome 9p21 is associated with the immortal phenotype of neoplastic human head and neck keratinocytes. Cancer Research 1994;54:5045-5049.
49. [49] Patel V, Jakus J, Harris C, Ensley JF, Robbins KC, Yendall WA. Altered expression and activity of Gl cyclin dependent kinases characterize squamous cell carcinomas of the head and neck, International Journal of Cancer 1998. In press.